Fri 2/28/2020 05:25 ET
DJIA25766.641138.894.42%TELCO178.906.463.61%GOLD1628.3514.170.87%Shanghai2890.5697.413.37%
S&P 5002978.76131.664.42%BANKS433.8319.614.52%OIL45.381.713.77%BITCOIN8655.29136.751.58%
NASDAQ8566.48394.914.61%PHARM575.4516.402.85%US/EU1.100.000.00%Futures2920.3836.501.25%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Wall Street Pit (Inovio Biomedical - INO)    Stock Due Diligence for All

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add INO
  
From: crainiac (Rep: 4161)Date: 01/23/2020 15:40
Forum: Wall Street Pit - Msg #2812658 - List INO msgs Thread #674118573 (Rec: 0)
Inovio's GLS-5300 - n The Lancet Infectious Diseases, Kayvon Modjarrad and colleagues1 reported results of the first in-human clinical trial of the GLS-5300 vaccine candidate against Middle East respiratory syndrome (MERS)coronavirus. The vaccine induced both humoral and cellular MERS coronavirus-specific immune responses. These data suggest that GLS-5300 has potential value in protecting humans from MERS coronavirus infections.

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30476-1/fulltext#%20

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser crainiac: Reward | Watch | IgnoreINO: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add INO
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.